Vor Biopharma (NASDAQ:VOR) Upgraded by Zacks Research to Strong Sell Rating

Key Points

• Vor Biopharma (NASDAQ:VOR) has been upgraded to a "strong sell" rating by Zacks Research, reflecting a negative outlook for the company's stock.
• The company's latest quarterly earnings report showed a loss of ($2.18) earnings per share, significantly missing analysts' consensus estimates of ($0.57).
• Vor Biopharma's stock was trading at $2.08 with a market cap of $263.49 million, having experienced a twelve month low of $0.13 and a high of $3.29.

Vor Biopharma (NASDAQ:VOR - Get Free Report) was upgraded by analysts at Zacks Research to a "strong sell" rating in a report issued on Tuesday, August 12th,Zacks.com reports.

VOR has been the topic of a number of other research reports. Wall Street Zen downgraded Vor Biopharma to a "strong sell" rating in a report on Saturday, June 28th. HC Wainwright upgraded Vor Biopharma from a "hold" rating to a "strong-buy" rating in a report on Monday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Vor Biopharma presently has a consensus rating of "Moderate Buy".

Vor Biopharma Trading Up 7.3%

Shares of VOR stock traded up $0.15 on Tuesday, reaching $2.20. 6,022,889 shares of the stock were exchanged, compared to its average volume of 7,952,958. The company has a market cap of $278.70 million, a P/E ratio of -0.16 and a beta of 2.06. Vor Biopharma has a twelve month low of $0.13 and a twelve month high of $3.29.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($2.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($1.61).

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.